

ASX RELEASE

Volpara signs five new contracts with a combined value of NZ\$12.3M

Highlights:

- Five, five-year contracts represent over US\$7.8M (NZ\$12.3M¹) in Total Contract Value (TCV)
- New contracts include some of the US’s leading healthcare providers Bon Secours Mercy Health, Northside Hospital, Adventist Health, Duly Health and Care, and Onsite Women’s Health
- Five-year renewal secured with Centura Health represents a further US\$887K (NZ\$1.4M¹) in TCV
- Agreements validate company’s focus on “elephant-sized” industry leaders for recurring revenue growth

Wellington, NZ, 9 January 2023: Volpara Health Technologies (“Volpara,” “the Group,” or “the Company”; ASX:VHT), a global leader in software for the early detection of breast cancer, today announced that it has signed five-year contracts with five of North America’s leading healthcare providers, representing over US\$7.8M in TCV (NZ\$12.3M¹).

The new volume-based contracts include the full breadth of Volpara software:

Deal	Customer Description	Contracted software	TCV
Bon Secours Mercy Health	The United States’ fifth largest Catholic health care ministry with 48 hospitals is one of the nation’s 20 largest health care systems	Volpara Risk Pathways™	US\$1.55M
Adventist Health	A faith-inspired, non-profit integrated health system serving more than 80 communities on the West Coast and Hawaii	Volpara Patient Hub™ Volpara Risk Pathways™ Volpara Scorecard™	US\$1.69M
Northside Hospital	One of Georgia’s leading health care systems serving 5 million patient annually.	Volpara Patient Hub™ Volpara Risk Pathways™ Volpara Scorecard™	US\$1.93M

¹ Twelve-month trailing exchange rate used of US\$0.636:NZ\$1.00

Duly Health and Care	The largest independent, multi-specialty physician-directed medical group in the Midwest	Volpara Analytics™ Volpara Risk Pathways™ Volpara Scorecard™	US\$1.45M
Onsite Women's Health	An innovator in the delivery of breast health services through a collaborative care model partnering with OB/GYN and primary care practices nationwide	Volpara Analytics™ Volpara Scorecard™	US\$1.19M

The company also announces that Centura Health, a 19-hospital health system serving patients across Colorado and western Kansas, has renewed for an additional five-years. The contract is a further US\$887K (NZ\$1.4M¹) in TCV.

Volpara Group CEO Teri Thomas said: "Volpara is delighted to partner with such large and well-respected organisations to save even more families from cancer. The growing demand for Volpara's breast software, which brings together cancer risk assessment, density scoring, image quality optimization, and patient tracking and reporting, reflects an industry transformation to more data-driven, personalized, high-quality care."

Thomas adds: "These new contracts are also representative of the "elephant" commercial opportunities Volpara is prioritizing to drive recurring revenue growth. The upgrades and renewals reflect the success providers rely on Volpara to deliver."

Installation is expected to occur within the next six to twelve months. All contracts are expected to contribute to revenue growth from FY24 onwards and all contracts are for an initial five-year subscription license term with annual payments. Each customer has the right to terminate their contract after 3 years, except for Bon Secours Mercy Health. Consideration paid upon signing for each contract is not considered material.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Teri Thomas, CEO

Volpara Health Technologies

teri.thomas@volparahealth.com

t: +64 4 499 6029

Hannah Howlett

WE Communications

WE-AUVolpara@we-worldwide.com

t: +61 407 933 437

About Volpara Health Technologies Limited (ASX:VHT)

Volpara Health Technologies makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 15 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A\$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com.